Dropless TriMoxi trial to begin in Canada

Advanced Dosage Forms Inc., the Canadian partner to Imprimis Pharmaceuticals, will begin a clinical trial of the Dropless TriMoxi formulation for cataract surgery, according to a press release.

The prospective, randomized, controlled, multicenter, crossover study will enroll 200 bilateral cataract surgery patients to compare Dropless TriMoxi (triamcinolone acetonide-moxifloxacin) to traditional eye drop therapy to assess drug safety, patient preference and pharmacoeconomic measures, the release said.

“The goal of the study is to clinically validate the experience of American ophthalmologists who have administered over 700,000 doses of this formulation to cataract surgery patients over the past 4 years,” Imprimis CEO Mark L. Baum said.

Advanced Dosage Forms Inc., the Canadian partner to Imprimis Pharmaceuticals, will begin a clinical trial of the Dropless TriMoxi formulation for cataract surgery, according to a press release.

The prospective, randomized, controlled, multicenter, crossover study will enroll 200 bilateral cataract surgery patients to compare Dropless TriMoxi (triamcinolone acetonide-moxifloxacin) to traditional eye drop therapy to assess drug safety, patient preference and pharmacoeconomic measures, the release said.

“The goal of the study is to clinically validate the experience of American ophthalmologists who have administered over 700,000 doses of this formulation to cataract surgery patients over the past 4 years,” Imprimis CEO Mark L. Baum said.